Remarkably, recent studies have revealed that clock-targeting compounds, such as REV-ERB agonists (e.g., SR9009 and SR9011) and/or CRY protein stabilizers (e.g., KL001 and SHP656), exhibit potent anti-cancer properties in glioblastoma, leukemia, breast, colon, and melanoma cancer cell lines by inhibiting autophagy and de novo lipogenesis that is important for cancer cell survival [123,148,149]. Here, CRYL1 is linked to cancer.